Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.
University of Oklahoma scientist secures nearly $1 million award to advance research in computational genomics
Marmar Moussa, Ph.D., an assistant professor of computer science professor at the University of Oklahoma, has secured a nearly $1 million award from the National
October 30, 2023